Single genetic defect produces specific cognitive deficit in miceSeptember 07, 2006Researchers have found that, in mice, producing a single genetic defect in a molecule that "reloads" neurons to trigger one another using the neurotransmitter acetylcholine impairs the mice's ability to recognize objects or other mice. The researchers, Marco Prado, Marc Caron, Vania Prado, and their colleagues, said their findings reveal a critical role in central nervous system (CNS) function for the component of the reloading machinery, called an acetylcholine transporter, that they knocked out. They also said their findings suggest that the mouse model will be useful in understanding how defects in neurons that use acetylcholine to trigger one another contribute to cognitive decline in such disorders as Alzheimer's disease (AD) and aging. The researchers published their finding in the September 7, 2006, issue of the journal Neuron, published by Cell Press. To explore the role of the acetylcholine transporter, the researchers genetically modified mice to either completely lack the transporter gene or to have reduced levels of it. Such transporters normally retrieve acetylcholine that one neuron has used to trigger another and transport it to storage sacs called vesicles that are the reservoir for neurotransmitter for subsequent use. The researchers found that such transporter-deficient mice were less able to fill such vesicles with acetylcholine. In behavioral tests, the researchers found that the mice with lower levels of the transporter were less able to learn to hang on to a rotating rod than normal mice. Mice completely lacking the transporter were totally unable to manage the task because they lacked physical endurance. Thus, wrote the researchers, those mice might be useful models for studying the effects of reduced acetylcholine release in certain neuromuscular disorders. Both normal mice and those with reduced transporter were equally able to learn and remember to avoid a mild shock. However, the reduced-transporter mice showed deficits in object recognition-significantly less able to remember that they had encountered specific-shaped plastic blocks before. The altered mice also showed less memory of "intruder" mice placed in their cages-evidence of reduced social recognition. Significantly, the researchers found that when they used a drug to enhance acetylcholine in the transporter-deficient mice, those mice showed improved performance on social recognition tests, implying that the deficit in social recognition was caused by a reduction in "cholinergic tone." Prado, Caron, and their colleagues concluded that "Our observations support the notion that reduced cholinergic tone in AD mouse models can indeed cause deficits in social memory. However, based on somewhat similar impairments found in the object and social recognition tasks, it is possible that mild cholinergic deficits may cause a more general memory deficit for recognizing previously learned complex cues, whether social or not. Future detailed investigations will be necessary to further define the specific type of cognitive processing affected by cholinergic deficits in these mutants. "Such studies in mouse models of reduced cholinergic tone may be particularly informative for understanding the contribution of cholinergic decline to specific behavioral alterations observed in certain pathologies of the CNS and may even be helpful in understanding physiological aging,\\\ Cell Press |
|||||||||||||||||||||
| Related Acetylcholine Current Events and Acetylcholine News Articles New Down syndrome treatment suggested by Stanford/Packard study in mice At birth, children with Down syndrome aren't developmentally delayed. But as they age, these kids fall behind. Memory deficits inherent in Down syndrome hinder learning, making it hard for the brain to collect experiences needed for normal cognitive development. Developmental delay could stem from nicotinic receptor deletion The loss of a gene through deletion of genetic material on chromosome 15 is associated with significant abnormalities in learning and behavior, said a consortium of researchers led by Baylor College of Medicine (www.bcm.edu) in a report that appears online today in the journal Nature Genetics. Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimer's People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications. Promising new treatment for Alzheimer's suggested based on Hebrew University research Research carried out at the Hebrew University of Jerusalem has resulted in a promising approach to help treat Alzheimer's disease in a significant proportion of the population that suffers from a particularly rapid development of this disease. Barrow researchers identify new brain receptor, possible target for Alzheimer's treatment Barrow Neurological Institute researchers have identified a novel receptor in the brain that is extremely sensitive to beta-amyloid peptide (AB) and may play a key role in early stages of Alzheimer's disease. Defeating nicotine's double role in lung cancer A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers. Genes: An extra hurdle to quitting smoking during pregnancy? Researchers from the Peninsula Medical School and the University of Bristol, using data from the Avon Longitudinal Study of Parents and Children and the Exeter Family Study of Childhood Health, have identified a common genetic variant that explains why some women may find it more difficult to quit smoking during pregnancy. Nicotine may have more profound impact than previously thought Nicotine isn't just addictive. It may also interfere with dozens of cellular interactions in the body, new Brown University research suggests. Caltech researchers find tiny genetic change keeps nicotine from binding to muscle cells A tiny genetic mutation is the key to understanding why nicotine--which binds to brain receptors with such addictive potency--is virtually powerless in muscle cells that are studded with the same type of receptor. Nose-spray vaccine against botulism effective in first tests A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy. More Acetylcholine Current Events and Acetylcholine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||